Summary of Study ST000396

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000309. The data can be accessed directly via it's Project DOI: 10.21228/M86G6V This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

Perform statistical analysis  |  Show all samples  |  Show named metabolites  |  Download named metabolite data  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files (Contains raw data)
Study IDST000396
Study TitleLung Cancer Plasma Discovery
Study SummaryRecently, major efforts have been directed toward early detection of lung cancer through low-dose computed tomography (LDCT) scanning. Data from the National Lung Screening Trial (NLST) suggest that yearly screening with thoracic LDCT scanning for high-risk current and former smokers reduces lung cancer mortality by 20% and total mortality by 7%. However, issues including indeterminate nodules detected by LDCT and radiation exposure impact the practicality of LDCT-based screening on a national and global basis. A blood-based biomarker or multiplexed marker panel that could complement LDCT would represent a major advance in implementing lung cancer screening. Efforts to develop blood-based biomarkers for lung cancer early detection using a variety of methodologies are currently ongoing. Proteomic studies have led to the identification of several candidate markers including pro-surfactantproteinB(pro-SFTPB), a target of a lineage-survival oncogene in lung cancer, NKX2-1.Validation studies using blood samples collected at the time of LDCT screening for lung cancer substantiated the performance of pro-SFTPB. Multivariable logistic regression models were used to evaluate the predictive ability of pro-SFTPB. The area under the curve (AUC) values of the full model with and without pro-SFTPB were 0.741 (95% CI, 0.696 to 0.783) and 0.669 (95%CI, 0.620 to 0.717), respectively (difference in AUC, P_.001). Single markers are unlikely to have sufficient performance for implementation in a screening setting, hence the need to explore several discovery platforms to identify markers that provide complementary performance. Metabolomics represents a global unbiased approach to the profiling of small molecules and has been established as a platform for biomarker discovery for a variety of human biofluids and tissues. Here we used an untargeted liquid chromatography/mass spectrometry (MS) metabolomics approach to identify metabolites that distinguish human sera collected before the diagnosis of lung cancer from matched control sera in a prospective cohort of highrisk patients from the Beta-Carotene and Retinol Efficacy Trial (CARET).
Institute
University of California, Davis
DepartmentGenome and Biomedical Sciences Facility
LaboratoryWCMC Metabolomics Core
Last NameFiehn
First NameOliver
Address1315 Genome and Biomedical Sciences Facility, 451 Health Sciences Drive, Davis, CA 95616
Emailofiehn@ucdavis.edu
Phone(530) 754-8258
Submit Date2016-05-10
Raw Data AvailableYes
Raw Data File Type(s)cdf
Analysis Type DetailGC-MS
Release Date2016-06-18
Release Version2
Release CommentsUpdated study design factors
Oliver Fiehn Oliver Fiehn
https://dx.doi.org/10.21228/M86G6V
ftp://www.metabolomicsworkbench.org/Studies/ application/zip

Select appropriate tab below to view additional metadata details:

Factors:

Subject type: Human; Subject species: Homo sapiens (Factor headings shown in green)

mb_sample_id local_sample_id Age Group Sex Smoking Status Diagnosis
SA018857110630bwasa12_245-49 Male Current -
SA018858110702bwasa44_145-49 Male Current -
SA018856110702bwasa17_145-49 Male Current Adenocarcinoma
SA018781110630bwasa49_250-54 Female Current -
SA018782110701bwasa11_250-54 Female Current -
SA018784110703bwasa31_150-54 Female Current -
SA018787110704bwasa08_150-54 Female Current -
SA018788110702bwasa09_150-54 Female Current -
SA018789110701bwasa33_250-54 Female Current -
SA018790110701bwasa44_150-54 Female Current -
SA018791110705bwasa20_150-54 Female Current -
SA018792110704bwasa24_150-54 Female Current -
SA018793110629bwasa50_250-54 Female Current -
SA018988110701bwasa35_250-54 Female Current -
SA018989110704bwasa28_150-54 Female Current -
SA019051110701bwasa09_250-54 Female Current -
SA019052110703bwasa23_150-54 Female Current -
SA018785110703bwasa24_150-54 Female Current Adenocarcinoma
SA018795110702bwasa25_150-54 Female Current Adenocarcinoma
SA018987110702bwasa30_150-54 Female Current Adenocarcinoma
SA019050110629bwasa47_250-54 Female Current Adenocarcinoma
SA018783110702bwasa24_150-54 Female Current Other NSCLC
SA018794110703bwasa35_150-54 Female Current Other NSCLC
SA018786110701bwasa34_250-54 Female Current Squamous cell
SA018860110704bwasa31_150-54 Female Former -
SA018861110703bwasa43_150-54 Female Former -
SA018862110704bwasa25_150-54 Female Former -
SA018863110704bwasa49_150-54 Female Former -
SA018864110701bwasa23_250-54 Female Former Adenocarcinoma
SA018859110705bwasa16_150-54 Female Former Other NSCLC
SA018760110629bwasa37_250-54 Male Current -
SA018761110701bwasa17_250-54 Male Current -
SA018773110701bwasa25_250-54 Male Current -
SA018774110702bwasa18_150-54 Male Current -
SA018866110704bwasa30_150-54 Male Current -
SA018867110702bwasa16_150-54 Male Current -
SA018868110703bwasa32_150-54 Male Current -
SA018870110703bwasa01_150-54 Male Current -
SA019029110703bwasa42_150-54 Male Current -
SA019030110629bwasa34_250-54 Male Current -
SA019032110702bwasa48_150-54 Male Current -
SA019033110701bwasa43_150-54 Male Current -
SA019035110702bwasa42_150-54 Male Current -
SA019037110701bwasa13_250-54 Male Current -
SA018772110630bwasa29_250-54 Male Current Adenocarcinoma
SA019031110629bwasa42_250-54 Male Current Adenocarcinoma
SA019034110701bwasa15_250-54 Male Current Adenocarcinoma
SA019036110705bwasa29_150-54 Male Current Adenocarcinoma
SA018762110703bwasa16_150-54 Male Current Squamous cell
SA018865110704bwasa07_150-54 Male Current Squamous cell
SA018869110703bwasa30_150-54 Male Current Squamous cell
SA018991110702bwasa15_150-54 Male Former -
SA018992110630bwasa30_250-54 Male Former -
SA019038110630bwasa36_250-54 Male Former -
SA019040110701bwasa29_350-54 Male Former -
SA018990110703bwasa03_150-54 Male Former Other NSCLC
SA019039110630bwasa27_250-54 Male Former Squamous cell
SA018796110630bwasa16_255-59 Female Current -
SA018797110704bwasa27_155-59 Female Current -
SA018801110630bwasa04_255-59 Female Current -
SA018802110630bwasa26_255-59 Female Current -
SA018803110701bwasa42_155-59 Female Current -
SA018804110701bwasa27_355-59 Female Current -
SA018841110630bwasa31_255-59 Female Current -
SA018842110630bwasa45_255-59 Female Current -
SA018994110702bwasa40_155-59 Female Current -
SA018995110630bwasa32_255-59 Female Current -
SA018799110630bwasa01_255-59 Female Current Adenocarcinoma
SA018800110704bwasa35_155-59 Female Current Adenocarcinoma
SA018843110703bwasa48_155-59 Female Current Other NSCLC
SA018798110701bwasa39_255-59 Female Current Squamous cell
SA018993110703bwasa37_155-59 Female Current Squamous cell
SA018775110704bwasa21_155-59 Male Current -
SA018777110704bwasa34_155-59 Male Current -
SA018805110629bwasa32_255-59 Male Current -
SA018806110629bwasa44_255-59 Male Current -
SA018807110704bwasa38_155-59 Male Current -
SA018811110704bwasa37_155-59 Male Current -
SA018812110703bwasa29_155-59 Male Current -
SA018813110704bwasa39_155-59 Male Current -
SA018872110630bwasa14_255-59 Male Current -
SA018874110704bwasa42_155-59 Male Current -
SA018875110702bwasa02_155-59 Male Current -
SA018876110702bwasa13_155-59 Male Current -
SA018951110630bwasa39_255-59 Male Current -
SA018952110705bwasa15_155-59 Male Current -
SA018953110705bwasa10_255-59 Male Current -
SA018954110704bwasa43_155-59 Male Current -
SA018776110703bwasa44_155-59 Male Current Adenocarcinoma
SA018809110702bwasa12_155-59 Male Current Adenocarcinoma
SA018871110702bwasa38_155-59 Male Current Adenocarcinoma
SA018873110629bwasa36_255-59 Male Current Adenocarcinoma
SA018955110702bwasa46_155-59 Male Current Adenocarcinoma
SA018808110703bwasa05_155-59 Male Current Other NSCLC
SA018810110703bwasa15_155-59 Male Current Squamous cell
SA018956110704bwasa03_155-59 Male Current Squamous cell
SA018764110703bwasa13_155-59 Male Former -
SA018765110703bwasa07_155-59 Male Former -
SA018878110630bwasa34_255-59 Male Former -
SA018879110630bwasa11_555-59 Male Former -
Showing page 1 of 3     Results:    1  2  3  Next     Showing results 1 to 100 of 299
  logo